NL300856I2 - - Google Patents

Download PDF

Info

Publication number: NL300856I2
Authority: NL; Netherlands
Prior art keywords: nucleotides; splice; polynucleotide; altered; replaced
Prior art date: 2004-06-18

Application number

NL300856C

Other languages

English (en)

Original Assignee

Molmed Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-06-18

Filing date

2016-12-29

Publication date

2017-04-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32750189&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL300856(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2016-12-29 Application filed by Molmed Spa filed Critical Molmed Spa

2017-04-20 Publication of NL300856I2 publication Critical patent/NL300856I2/nl

Links

239000002773 nucleotide Substances 0.000 abstract 5
125000003729 nucleotide group Chemical group 0.000 abstract 5
108020005067 RNA Splice Sites Proteins 0.000 abstract 2
102000006601 Thymidine Kinase Human genes 0.000 abstract 1
108020004440 Thymidine kinase Proteins 0.000 abstract 1
108091033319 polynucleotide Proteins 0.000 abstract 1
239000002157 polynucleotide Substances 0.000 abstract 1
102000040430 polynucleotide Human genes 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
- C12N9/1211—Thymidine kinase (2.7.1.21)

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Genetics & Genomics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Microbiology (AREA)
Immunology (AREA)
Oncology (AREA)
Epidemiology (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Vascular Medicine (AREA)
Tropical Medicine & Parasitology (AREA)
Transplantation (AREA)
Pulmonology (AREA)
Physics & Mathematics (AREA)
Biophysics (AREA)
Plant Pathology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)

NL300856C 2004-06-18 2016-12-29 NL300856I2 (nl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0413702.2A GB0413702D0 (en)	2004-06-18	2004-06-18	Thymidine kinase
PCT/IB2005/002358 WO2005123912A2 (en)	2004-06-18	2005-06-17	Thymidine kinase

Publications (1)

Publication Number	Publication Date
NL300856I2 true NL300856I2 (nl)	2017-04-20

Family

ID=32750189

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NL300856C NL300856I2 (nl)	2004-06-18	2016-12-29

Country Status (20)

Country	Link
US (5)	US8357788B2 (nl)
EP (1)	EP1781789B1 (nl)
JP (1)	JP5091669B2 (nl)
KR (1)	KR101337210B1 (nl)
CN (1)	CN101010428B (nl)
AT (1)	ATE520779T1 (nl)
AU (1)	AU2005254807B2 (nl)
CA (1)	CA2569304C (nl)
CY (2)	CY1111925T1 (nl)
DK (1)	DK1781789T3 (nl)
ES (1)	ES2372022T3 (nl)
GB (1)	GB0413702D0 (nl)
HU (1)	HUS1600064I1 (nl)
IL (2)	IL179660A (nl)
LT (1)	LTC1781789I2 (nl)
NL (1)	NL300856I2 (nl)
PL (1)	PL1781789T3 (nl)
PT (1)	PT1781789E (nl)
SI (1)	SI1781789T1 (nl)
WO (1)	WO2005123912A2 (nl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0413702D0 (en)	2004-06-18	2004-07-21	Molmed Spa	Thymidine kinase
AU2012320480A1 (en)	2011-10-05	2014-04-24	Molmed Spa	Viral vectors purification system
AU2018395012B2 (en)	2017-12-28	2022-03-10	Bionoxx Inc.	Oncolytic virus improved in safety and anticancer effect
US11157042B1 (en)	2018-03-28	2021-10-26	Douglas Patton	Systems and methods for interaction of wearable communication devices
JP2021525066A (ja)	2018-05-30	2021-09-24	グリコステムセラピューティクスベスローテンフェンノートシャップ	Ｃａｒｎｋ細胞
CA3139643A1 (en) *	2019-06-27	2020-12-30	Bionoxx Inc.	Oncolytic virus with improved safety and anticancer effects
WO2025168661A1 (en)	2024-02-05	2025-08-14	Ospedale San Raffaele S.R.L.	Chimeric antigen receptor

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69033975T2 (de) *	1989-01-23	2002-10-02	Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville	Rekombinanttherapien für Infektionen und hyperproliferative Störungen
JP2752788B2 (ja)	1989-01-23	1998-05-18	カイロンコーポレイション	感染および過剰増殖障害の為の組換え療法
US5631236A (en) *	1993-08-26	1997-05-20	Baylor College Of Medicine	Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
IT1261847B (it)	1993-09-01	1996-06-03	San Romanello Centro Fond	Metodo per marcare cellule eucariote.
FR2712603B1 (fr)	1993-11-18	1996-02-09	Centre Nat Rech Scient	Virus recombinants, préparation et utilisation en thérapie génique.
US5877010A (en) *	1994-05-02	1999-03-02	University Of Washington	Thymidine kinase mutants
SK107998A3 (en)	1996-02-09	1999-01-11	Rhone Poulenc Rorer Sa	Variants of thymidine kinase, related nucleic acids sequences and their use in genic therapy
FR2751988B1 (fr)	1996-08-01	1998-09-11	Rhone Poulenc Rorer Sa	Nouveaux variants de la thymidine kinase, sequences d'acides nucleiques correspondantes et leur utilisation en therapie genique
FR2744731B1 (fr)	1996-02-09	1998-05-22	Rhone Poulenc Rorer Sa	Nouveaux variants de la thymidine kinase, sequences d'acides nucleiques correspondantes et leur utilisation en therapie genique
WO1997037542A1 (en)	1996-04-10	1997-10-16	University Of Southern California	Gene therapy for proliferative vitreoretinopathy
EP1886677A1 (en)	1996-07-26	2008-02-13	Susan P. Perrine	Use of an inducing agent for the treatment of blood, viral and cellular disorders
DE69838483T2 (de)	1997-10-14	2008-07-03	Darwin Molecular Corp.	Thymidinkinase mutanten und fusionproteine mit thymidinkinase und guanylatekinase aktivitäten
GB0008966D0 (en) *	2000-04-13	2000-05-31	Imp College Innovations Ltd	Vectors for gene therapy
CN1273587C (zh) *	2002-06-05	2006-09-06	上海新世界基因技术开发有限公司	疱疹病毒胸苷激酶突变体及其应用
EP1428886B1 (de)	2002-12-09	2009-08-05	Celltech GmbH Biotechnologie	Verbesserte retrovirale Vektoren für die Gentherapie
GB0413702D0 (en)	2004-06-18	2004-07-21	Molmed Spa	Thymidine kinase

2004
- 2004-06-18 GB GBGB0413702.2A patent/GB0413702D0/en not_active Ceased
2005
- 2005-06-17 WO PCT/IB2005/002358 patent/WO2005123912A2/en not_active Ceased
- 2005-06-17 PL PL05766582T patent/PL1781789T3/pl unknown
- 2005-06-17 AU AU2005254807A patent/AU2005254807B2/en not_active Ceased
- 2005-06-17 US US11/629,962 patent/US8357788B2/en not_active Expired - Fee Related
- 2005-06-17 AT AT05766582T patent/ATE520779T1/de active
- 2005-06-17 EP EP05766582A patent/EP1781789B1/en not_active Expired - Lifetime
- 2005-06-17 JP JP2007516075A patent/JP5091669B2/ja not_active Expired - Fee Related
- 2005-06-17 DK DK05766582.0T patent/DK1781789T3/da active
- 2005-06-17 PT PT05766582T patent/PT1781789E/pt unknown
- 2005-06-17 KR KR1020077001055A patent/KR101337210B1/ko not_active Expired - Fee Related
- 2005-06-17 CN CN2005800286686A patent/CN101010428B/zh not_active Expired - Fee Related
- 2005-06-17 ES ES05766582T patent/ES2372022T3/es not_active Expired - Lifetime
- 2005-06-17 CA CA2569304A patent/CA2569304C/en not_active Expired - Fee Related
- 2005-06-17 SI SI200531385T patent/SI1781789T1/sl unknown
2006
- 2006-11-28 IL IL179660A patent/IL179660A/en active IP Right Grant
2011
- 2011-05-24 IL IL213084A patent/IL213084A0/en unknown
- 2011-10-10 CY CY20111100964T patent/CY1111925T1/el unknown
2012
- 2012-08-31 US US13/601,174 patent/US8642311B2/en not_active Expired - Fee Related
2013
- 2013-12-10 US US14/101,704 patent/US9005945B2/en not_active Expired - Fee Related
2015
- 2015-04-01 US US14/676,696 patent/US10155052B2/en not_active Expired - Fee Related
2016
- 2016-12-28 CY CY2016054C patent/CY2016054I1/el unknown
- 2016-12-28 LT LTPA2016047C patent/LTC1781789I2/lt unknown
- 2016-12-29 NL NL300856C patent/NL300856I2/nl unknown
- 2016-12-30 HU HUS1600064C patent/HUS1600064I1/hu unknown
2018
- 2018-11-15 US US16/192,224 patent/US10314925B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
ES2372022T3 (es)	2012-01-13
EP1781789A2 (en)	2007-05-09
US20150231275A1 (en)	2015-08-20
IL213084A0 (en)	2011-07-31
US20090130069A1 (en)	2009-05-21
CA2569304C (en)	2014-08-12
US20190070312A1 (en)	2019-03-07
EP1781789B1 (en)	2011-08-17
ATE520779T1 (de)	2011-09-15
US8642311B2 (en)	2014-02-04
CY2016054I2 (el)	2017-07-12
PL1781789T3 (pl)	2011-12-30
LTC1781789I2 (lt)	2018-10-10
IL179660A0 (en)	2007-05-15
CA2569304A1 (en)	2005-12-29
DK1781789T3 (da)	2011-11-28
US20140178345A1 (en)	2014-06-26
US20130028876A1 (en)	2013-01-31
KR101337210B1 (ko)	2013-12-06
CN101010428B (zh)	2013-10-02
JP5091669B2 (ja)	2012-12-05
HK1097881A1 (en)	2007-07-06
JP2008502342A (ja)	2008-01-31
PT1781789E (pt)	2011-10-20
CN101010428A (zh)	2007-08-01
US8357788B2 (en)	2013-01-22
IL179660A (en)	2012-12-31
HUS1600064I1 (hu)	2017-02-28
KR20070032786A (ko)	2007-03-22
CY2016054I1 (el)	2017-07-12
AU2005254807A1 (en)	2005-12-29
LTPA2016047I1 (lt)	2017-01-25
US10155052B2 (en)	2018-12-18
GB0413702D0 (en)	2004-07-21
WO2005123912A3 (en)	2006-05-04
AU2005254807B2 (en)	2011-08-18
US9005945B2 (en)	2015-04-14
US10314925B2 (en)	2019-06-11
CY1111925T1 (el)	2015-11-04
WO2005123912A2 (en)	2005-12-29
SI1781789T1 (sl)	2012-03-30

Publication	Publication Date	Title
HUS1600064I1 (hu)	2017-02-28	Timidin kináz
GB0909600D0 (en)	2009-07-15	Four-color DNA sequencing by synthesis using cleavable fluorescent nucleotide reversible terminators
AU2003262906A8 (en)	2004-03-19	Bioreactors with multiple chambers
WO2010018577A3 (en)	2010-08-19	Data entry system
AR056256A1 (es)	2007-10-03	Plantas resistentes al estres
WO2008087561A3 (en)	2009-04-09	Methods and compositions for modulating the sirna and rna-directed-dna methylation pathways
ATE430589T1 (de)	2009-05-15	Wasserbehandlung zur kontrolle von biobewuchs mittels stabilisierter bromlösungen
TW200630362A (en)	2006-09-01	(2-carboxamido)(3-amino)thiophene compounds
ATE490954T1 (de)	2010-12-15	Estergebundene geminitensidverbindungen zur verwendung in der gentherapie
WO2008146745A1 (ja)	2008-12-04	新規なリゾホスファチジン酸アシル基転移酵素遺伝子
NO20100724L (no)	2010-05-28	Ledende sementformulering og anvendelse av denne i en bronn
TW200510510A (en)	2005-03-16	Polyquinoline copolymer and organic electroluminescence element using the same
MXPA05007538A (es)	2005-09-21	Gen resistente a aphis gossypii.
DE602005026326D1 (de)	2011-03-24	Phosphitester enthaltende stabilisatorzusammensetzung
NO20091016L (no)	2009-03-30	Pyridooksazepin-progesteron reseptormodulatorer
DE50300919D1 (de)	2005-09-08	Verwendung eines magnesiazirkoniasteins
ATE543828T1 (de)	2012-02-15	Heteropolynukleotid-duplexe mit purin-purin- paarung
AR054577A1 (es)	2007-06-27	Gen y enzima glucano diquinasa de chlamydomonas reinharft ii almidon modificado sus usos y metodos de produccion
TW200834278A (en)	2008-08-16	Multiplier-divider with error compensation function
DE602007013084D1 (de)	2011-04-21	Neues markiertes oligonukleotid
ATE361081T1 (de)	2007-05-15	Verwendung von 5-substituierten nukleosiden zur verstärkung der apoptotischen wirkung von zytostatika
DK2254950T3 (da)	2012-01-23	1,3-thiazolyl-azo-farvestoffer, deres frembringelse og anvendelse
DK1478664T3 (da)	2011-01-31	Vævsspecifik ekspression
AU314699S (en)	2007-06-18	Umbrellas - outside shade structures
FR2853906B1 (fr)	2006-04-14	N-desoxyribosyltransferases de lactobacilles, sequences nucleotidiques correspondantes et leurs applications